Skip to main content
Top
Published in: Clinical Rheumatology 7/2008

01-07-2008 | Original Article

Primary antiphospholipid syndrome in Latin American mestizo patients: clinical and immunologic characteristics and comparison with European patients

Authors: Rossana Mejía-Romero, Mario García-Carrasco, Claudio Galarza-Maldonado, Pedro Santos, Claudia Mendoza-Pinto, Ricardo O. Escárcega, Salvador Salinas-Saldivar, Elena Soto-Vega, Aurelio López-Colombo, Ricard Cervera

Published in: Clinical Rheumatology | Issue 7/2008

Login to get access

Abstract

A great variety of clinical and immunological features have been described in patients with the antiphospholipid syndrome (APS), but information on their prevalence and characteristics in Latin American mestizo patients with the primary APS is scarce. To analyze the prevalence and characteristics of the main clinical and immunological manifestations in a cohort of patients with primary APS of mestizo origin from Latin America and to compare them with the European white patients, clinical and serological characteristics of 100 patients with primary APS from Colombia, Mexico, and Ecuador were collected in a protocol form that was identical to that used to study the “Euro-Phospholipid” cohort. The cohort consisted of 92 female patients (92.0%) and eight (8.0%) male patients. They were all mestizos. The most common manifestations were deep vein thrombosis (DVT; 23.0%), livedo reticularis (18.0%), migraine (18.0%), and stroke (18.0%). The most common pregnancy morbidity was early pregnancy losses (54.1% of pregnancies). Several clinical manifestations were more prevalent in the Latin American mestizo than in the European patients (transient global amnesia, pulmonary microthrombosis, arthralgias, and early pregnancy losses) and vice-versa (DVT, stroke, pulmonary embolism, and thrombocytopenia). Latin American mestizo patients with primary APS have a wide variety of clinical and immunological manifestations with several differences in their prevalence in comparison with European white patients.
Literature
1.
go back to reference Asherson RA, Cervera R, Piette JC, Shoenfeld Y (2002) Milestones in the antiphospholipid syndrome. In: Asherson R-A, Cervera R, Piette JC, Shoenfeld Y (eds) The antiphospholipid syndrome II—autoimmune thrombosis. Elsevier, Amsterdam, pp 3–9CrossRef Asherson RA, Cervera R, Piette JC, Shoenfeld Y (2002) Milestones in the antiphospholipid syndrome. In: Asherson R-A, Cervera R, Piette JC, Shoenfeld Y (eds) The antiphospholipid syndrome II—autoimmune thrombosis. Elsevier, Amsterdam, pp 3–9CrossRef
2.
go back to reference Font J, López-Soto A, Cervera R, Balasch J, Pallarés L, Navarro M et al (1991) The ‘primary’ antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients. Autoimmunity 9:69–75PubMedCrossRef Font J, López-Soto A, Cervera R, Balasch J, Pallarés L, Navarro M et al (1991) The ‘primary’ antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients. Autoimmunity 9:69–75PubMedCrossRef
3.
go back to reference Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RHWM, Machin SJ, Barquinero J et al (1989) The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 68:366–374 Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RHWM, Machin SJ, Barquinero J et al (1989) The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 68:366–374
4.
go back to reference Alarcón-Segovia D, Delezé M, Oria CV, Sánchez-Guerrero J, Gómez-Pacheco L, Cabiedes J et al (1989) Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 68:353–365 Alarcón-Segovia D, Delezé M, Oria CV, Sánchez-Guerrero J, Gómez-Pacheco L, Cabiedes J et al (1989) Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 68:353–365
5.
go back to reference Muñoz-Rodríguez FJ, Font J, Cervera R, Reverter JC, Tàssies D, Espinosa G et al (1999) Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 29:182–190PubMedCrossRef Muñoz-Rodríguez FJ, Font J, Cervera R, Reverter JC, Tàssies D, Espinosa G et al (1999) Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 29:182–190PubMedCrossRef
6.
go back to reference Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, López-Soto A et al (1994) Comparison of the primary and secondary antiphospholipid syndrome. A European multicenter study of 131 patients. Am J Med 96:3–9PubMedCrossRef Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, López-Soto A et al (1994) Comparison of the primary and secondary antiphospholipid syndrome. A European multicenter study of 131 patients. Am J Med 96:3–9PubMedCrossRef
7.
go back to reference Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC et al (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12:530–534PubMedCrossRef Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC et al (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12:530–534PubMedCrossRef
8.
go back to reference Uthman I, Khamashta M (2005) Ethnic and geographical variation in antiphospholipid (Hughes) syndrome. Ann Rheum Dis 64:1671–1676PubMedCrossRef Uthman I, Khamashta M (2005) Ethnic and geographical variation in antiphospholipid (Hughes) syndrome. Ann Rheum Dis 64:1671–1676PubMedCrossRef
9.
go back to reference Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027PubMedCrossRef Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027PubMedCrossRef
10.
go back to reference Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostas 4:295–306CrossRef Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostas 4:295–306CrossRef
11.
go back to reference Piette JC, Wechsler B, Francès C, Papo T, Godeau P (1993) Exclusion criteria for primary antiphospholipid syndrome. J Rheumatol 20:1802–1804PubMed Piette JC, Wechsler B, Francès C, Papo T, Godeau P (1993) Exclusion criteria for primary antiphospholipid syndrome. J Rheumatol 20:1802–1804PubMed
12.
go back to reference Tan EM, Cohen AS, Fries J, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef Tan EM, Cohen AS, Fries J, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef
13.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
15.
go back to reference Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef
16.
go back to reference Hunder GG, Arend WP, Bloch DA, Calabrese LH, Fauci AS, Fries JF et al (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Arthritis Rheum 33:1065–1144PubMedCrossRef Hunder GG, Arend WP, Bloch DA, Calabrese LH, Fauci AS, Fries JF et al (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Arthritis Rheum 33:1065–1144PubMedCrossRef
17.
go back to reference Harris EN, Gharavi AE, Patel SP, Hughes GRV (1987) Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 68:215–222PubMed Harris EN, Gharavi AE, Patel SP, Hughes GRV (1987) Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 68:215–222PubMed
18.
go back to reference Brandt JT, Triplett DA, Alving B, Scharrer I (1995) Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 74:1185–1190PubMed Brandt JT, Triplett DA, Alving B, Scharrer I (1995) Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 74:1185–1190PubMed
19.
go back to reference Medina G, Vera-Lastra O, Angeles U, Jara LJ (2005) Mono-organic versus multiorganic involvement in primary antiphospholipid syndrome. Ann N Y Acad Sci 1051:304–312PubMedCrossRef Medina G, Vera-Lastra O, Angeles U, Jara LJ (2005) Mono-organic versus multiorganic involvement in primary antiphospholipid syndrome. Ann N Y Acad Sci 1051:304–312PubMedCrossRef
20.
go back to reference Gómez-Puerta JA, Martin H, Amigo MC, Aguirre MA, Camps MT, Cuadrado MJ et al (2005) Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore) 84:225–230CrossRef Gómez-Puerta JA, Martin H, Amigo MC, Aguirre MA, Camps MT, Cuadrado MJ et al (2005) Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore) 84:225–230CrossRef
21.
go back to reference Stojanovich L (2006) Pulmonary manifestations in antiphospholipid syndrome. Autoimmun Rev 5:344–348PubMedCrossRef Stojanovich L (2006) Pulmonary manifestations in antiphospholipid syndrome. Autoimmun Rev 5:344–348PubMedCrossRef
22.
go back to reference Krause I, Blank M, Fraser A (2005) The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiol 210:749–754CrossRef Krause I, Blank M, Fraser A (2005) The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiol 210:749–754CrossRef
23.
go back to reference Cucurull E, Espinoza LR, Mendez E, Molina JF, Molina J, Ordi-Ros J et al (1999) Anticardiolipin and anti-β2-glycoprotein I antibodies in patients with systemic lupus erythematosus: comparison between Colombians and Spaniards. Lupus 8:134–141PubMedCrossRef Cucurull E, Espinoza LR, Mendez E, Molina JF, Molina J, Ordi-Ros J et al (1999) Anticardiolipin and anti-β2-glycoprotein I antibodies in patients with systemic lupus erythematosus: comparison between Colombians and Spaniards. Lupus 8:134–141PubMedCrossRef
Metadata
Title
Primary antiphospholipid syndrome in Latin American mestizo patients: clinical and immunologic characteristics and comparison with European patients
Authors
Rossana Mejía-Romero
Mario García-Carrasco
Claudio Galarza-Maldonado
Pedro Santos
Claudia Mendoza-Pinto
Ricardo O. Escárcega
Salvador Salinas-Saldivar
Elena Soto-Vega
Aurelio López-Colombo
Ricard Cervera
Publication date
01-07-2008
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 7/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0818-4

Other articles of this Issue 7/2008

Clinical Rheumatology 7/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.